Canari noir

Adenia Closes Fifth Flagship Fund Oversubscribed at $470M

Retrieved on: 
Wednesday, April 3, 2024
Banking, Professional Services, Finance, Professional, DEG, DFI, Partner, Growth, Partner (business rank), Health, Education, ESG, Canari noir, Acquisition, AC, Investment, FMO, Air Liquide, Renewable energy, EIB, Telecommunications, Fund, DFC, CEP

Adenia Partners (“Adenia”), a leading private equity firm focused on growth opportunities in Africa, has successfully closed its fifth fund, Adenia Capital V (the “Fund”, “AC(V)” or “Fund V”) at its $470 million hard cap.

Key Points: 
  • Adenia Partners (“Adenia”), a leading private equity firm focused on growth opportunities in Africa, has successfully closed its fifth fund, Adenia Capital V (the “Fund”, “AC(V)” or “Fund V”) at its $470 million hard cap.
  • The Fund, which was significantly oversubscribed, attracted commitments from new and existing investors globally.
  • The Fund is sector-agnostic with financial services, agribusiness, renewable energy, consumer goods, telecommunications, healthcare and education, business services, light manufacturing, and specialty distribution as areas of particular focus.
  • As Adenia’s first completely pan-African fund, Fund V will leverage the firm’s extensive on-the-ground presence with seven offices on the continent.

Adenia Announces First Investment for Fifth Flagship Fund

Retrieved on: 
Tuesday, October 10, 2023
Professional Services, Other Energy, Utilities, Alternative Energy, Energy, Finance, Knowledge, Farm, School, Climate change, South African Reserve Bank, ESG, CO2, SARB, Carbon, Electricity, Fund, Growth, Environmental issues, Social and environmental impact of palm oil, Social, Partner, Quality of life, Renewable energy, Adenia, African, Canari noir

Adenia Partners (“Adenia”), a private markets investment firm committed to responsible investing and a sustainable Africa, has completed a majority investment in Enfin, a solar financing solutions provider serving commercial and industrial clients across South Africa, as the first investment from its fifth flagship fund (“Adenia V” or “the Fund”).

Key Points: 
  • Adenia Partners (“Adenia”), a private markets investment firm committed to responsible investing and a sustainable Africa, has completed a majority investment in Enfin, a solar financing solutions provider serving commercial and industrial clients across South Africa, as the first investment from its fifth flagship fund (“Adenia V” or “the Fund”).
  • The investment comes at a time when South Africa’s long-running energy crisis has significantly escalated, impacting economic growth and the quality of life for millions of people.
  • The South African Reserve Bank (SARB) has predicted 250 days of power blackout in 2023, equating to an economic loss of more than $13 billion.
  • At the firm level, Adenia is committed to be carbon neutral by 2027.

Inventiva publie ses résultats annuels 2021 : Avancées majeures avec lanifibranor dans la NASH et cedirogant dans le psoriasis

Retrieved on: 
Monday, March 7, 2022
The Others (1974 film), Security (finance), Par les fils de Mandrin, NASH, The New England Journal of Medicine, Canari noir, CIR, PGE, Euronext Paris, NAFLD, Notre, IFRS, POSI, Patient, Psoriasis, AbbVie, LEGEND, Comte, ATM, Pension fund, Department store, Film, Nightclub, Lithium

Inventiva a galement annonc le design de LEGEND, un essai clinique de Phase II avec lanifibranor et l'empagliflozine, un inhibiteur SGLT2, chez des patients atteints de NASH et de diabte de type 2.

Key Points: 
  • Inventiva a galement annonc le design de LEGEND, un essai clinique de Phase II avec lanifibranor et l'empagliflozine, un inhibiteur SGLT2, chez des patients atteints de NASH et de diabte de type 2.
  • Nous sommes convaincus que la publication des rsultats de notre tude clinique NATIVE de Phase IIb par le The New England Journal of Medicine a galement renforc la lgitimit de lanifibranor comme traitement potentiel de rfrence pour la NASH.
  • La combinaison de ces progrs en matire de dveloppement clinique et ces rsultats financiers renforce notre grande confiance en l'avenir.
  • Dans le cadre de sa collaboration avec AbbVie dans les maladies auto-immunes, Inventiva est ligible la rception dventuels paiements d'tape de dveloppement, rglementaires et commerciaux, ainsi que des paiements de redevances de la part dAbbVie.